One To Watch

Seamless Therapeutics

A gene editing company with operations in Dresden, Germany and Lexington, Massachusetts. The organization is structured with R&D activities spanning both sites, supporting discovery through early development.

Founding and History

Seamless Therapeutics was launched as a spin-out from Technische Universität Dresden to develop programmable recombinase-based gene editing. The company reported an initial $12.5 million seed round in 2023, followed by additional seed financing disclosed in 2024 alongside a U.S. expansion and establishment of Seamless Tx Inc. in Lexington, Massachusetts.

Therapy Areas and Focus

Seamless is focused on genetic medicines where large, precise DNA edits are required. The company frames its approach as applicable across a broad range of severe diseases, with flexibility to address multiple pathogenic variants within a given gene or locus.

Technology Platforms and Modalities

Seamless develops programmable recombinases—engineered enzymes designed to excise, insert, invert, or exchange defined DNA segments at targeted genomic sites. The platform emphasis is on:

Large, precise edits (gene-sized insertions/deletions or inversions)
Editing that is positioned as independent of the cell’s DNA repair pathways
Programmability intended to enable targeting across different loci rather than being constrained to a narrow set of sequences

The company positions this as a differentiated alternative to nuclease-based editing where outcomes can depend on DNA break repair and may be constrained for large sequence changes.

Key Personnel

Albert Seymour, PhD, President and Chief Executive Officer

Deborah Kinch, PhD, Chief Development Officer

Felix Lansing, PhD, Co-Founder and Chief Technology Officer

Anne-Kristin Heninger, PhD, Co-Founder, Head of Operations and Managing Director (Germany)

Adam Rosenberg, Chairman of the Board

Strategic Partnerships

Seamless uses partnerships to translate its recombinase platform into therapeutic programs. In January 2026, the company announced a global research collaboration with Eli Lilly focused on developing programmable recombinase-based genetic medicines for defined hearing loss indications, with Seamless responsible for designing/programming recombinases and Lilly leading downstream development and commercialization.

FAQ Section

Seamless develops programmable recombinases for targeted gene editing. The platform is designed to enable large, precise DNA edits—such as insertions, deletions, inversions, and exchanges—at specified genomic sites.

Seamless is positioned as a genetic medicines company targeting severe diseases where durable correction requires larger sequence changes than simple point edits. Specific initial indications have been shaped through partnerships and internal prioritization.

Seamless is at the preclinical stage. Public disclosures emphasize platform capability and partnership-led program definition rather than a list of named clinical candidates.

January 28, 2026: Seamless announced a global research collaboration with Eli Lilly to develop programmable recombinase-based therapeutics for hearing loss.

April 2024: the company announced a CEO appointment, a board chair appointment, and expansion of U.S. R&D operations in Lexington, Massachusetts, alongside disclosure of total seed financing raised to date.

Seamless has highlighted preclinical proof-of-concept consistent with large-fragment editing capabilities and has used peer-reviewed and conference-linked updates to support technical positioning of programmable recombinases.

Near-term milestones are expected to be preclinical: target selection, in vivo validation, manufacturability and delivery strategy development, and IND-enabling work for initial programs, including collaboration-led candidates.

Seamless is led by executives with experience in genetic medicines development and operations. The operating model combines platform build-out with partnered program execution, with R&D structured across Germany and the U.S.

Want to Update your Company's Profile?